ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 589

A Survey Of Physician and Patient Satisfaction With Control Of Systemic Lupus Erythematosus and Lupus Nephritis

Neelufar Mozaffarian1, Steve Lobosco2 and Adam Roughley2, 1AbbVie, North Chicago, IL, 2Adelphi Real World Ltd., Macclesfield, United Kingdom

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Lupus, Lupus nephritis, Patient Satisfaction, systemic lupus erythematosus (SLE) and treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects I - Renal, Malignancy, Cardiovascular Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose: Patient satisfaction with disease control is an important component of overall health and well-being. Current treatment options for systemic lupus erythematosus (SLE) ±lupus nephritis (LN) include antimalarials, glucocorticoids, and immune modulators, but unmet treatment needs remain. The objectives of this analysis were to evaluate (1) patient and physician satisfaction with treatment–mediated disease control and (2) degree of physician–patient agreement with respect to treatment satisfaction.

Methods: Data were extracted from the Adelphi Real World Lupus Disease–Specific Programme®, a cross–sectional US survey of 50 rheumatologists, 25 nephrologists, and their consulting patients, conducted December 2009–May 2010. Each physician completed a comprehensive form regarding his or her 5 most recent lupus patients (N=375); data collected included disease severity, treatment history, and current therapy(ies). Physician– and patient–reported satisfaction with the level of disease control was assessed using a 3–point scale.

Results: Physician–reported data were obtained regarding 168 patients with non–nephritis SLE (NNSLE), 164 of whom were treated by rheumatologists, and 206 LN–patients, 120 of whom were treated by nephrologists; patient–reported data were obtained from 212 of these patients (NNSLE, 99; LN, 113). Physicians were satisfied with disease control in 79% (132/168) of NNSLE–patients; 76% (75/99) of NNSLE–patients were satisfied. However, agreement (71%) on the level of satisfaction with disease control among NNSLE–patients and their rheumatologists was “slight” (kappa=.1445). Notably, agreement on the level of satisfaction with disease control declined significantly with NNSLE severity (p=.0062); the greatest agreement was observed for mild NNSLE (59/75; 79%), with less agreement for moderate NNSLE (9/21; 43%) or severe NNSLE (2/3; 67%). As the number of drugs taken by NNSLE–patients increased, agreement on the level of satisfaction decreased (nonsignificant trend, p=.2035): 1 drug, 22/27 (81%); 2 drugs, 22/30 (73%); ≥3 drugs, 26/42 (62%).

Physicians were satisfied with disease control in 74% (152/206) of LN–patients; 65% (74/113) of LN–patients were satisfied. Agreement (71%) on the level of satisfaction among LN–patients (112) and their nephrologists was “fair” (kappa=.3695). Agreement tended to be higher (nonsignificant trend [p=.0740]) in patients with mild (42/56; 75%) or moderate LN (31/41; 76%), compared with severe LN (7/15; 47%). As the number of drugs taken by LN–patients increased, agreement on the level of satisfaction decreased (nonsignificant trend, p=.0764): 1 drug, 17/20 (85%); 2 drugs, 30/39 (77%); ≥3 drugs, 31/51 (61%).

Conclusion: For NNSLE, 21% of rheumatologists and 24% of patients were not satisfied with the level of disease control. For LN, 26% of nephrologists and 35% of patients were not satisfied with the level of disease control. Patients with more severe disease and those taking a higher number of anti–lupus drugs were less likely to agree with their physicians’ level of satisfaction. These disease–control disparities highlight the need for more effective treatment options for both NNSLE and LN.


Disclosure:

N. Mozaffarian,

AbbVie,

9,

AbbVie,

1;

S. Lobosco,

Adelphi Real World Ltd. ,

3;

A. Roughley,

Adelphi Real World Ltd.,

3.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-survey-of-physician-and-patient-satisfaction-with-control-of-systemic-lupus-erythematosus-and-lupus-nephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology